Does Ilumya treat psoriatic arthritis?
Ilumya is not approved by the FDA to treat psoriatic arthritis, but studies for this use are ongoing. Illumya is only approved to treat plaque psoriasis at this time. Your doctor may decide, based on their medical judgement, to prescribe Ilumya off-label for other conditions.
"Off-label" use of a drug refers to prescribing a medication for a different purpose than those formally approved by the FDA and found in the package labeling of the drug.
Ilumya (tildrakizumab-asmn) is a prescription injection used to treat moderate-to-severe plaque psoriasis in adults. Ilumya is an injection given under the skin (subcutaneously).
- Ilumya is used in patients who may benefit from receiving injections, pills, or treatment with ultraviolet (UV) light phototherapy.
- It is classified as a humanized, anti-IL-23p19 monoclonal antibody and works by blocking inflammatory proteins (cytokines and chemokines) in the body.
- Sun Pharma is the manufacturer of Ilumya.
Psoriatic arthritis is an inflammatory form of arthritis also associated with psoriasis plaques of the skin. Psoriatic arthritis can affect over 40% of patients with plaque psoriasis. Symptoms include joint pain, swelling and stiffness, fatigue and loss of ability to fully use the joint.
Common treatments approved by the FDA to treat both psoriatic arthritis and plaque psoriasis include:
Related questions
- What does psoriasis look like?
- How do you get psoriasis and is it contagious?
- How does Tremfya work to treat plaque and psoriatic arthritis?
Studies of Ilumya for psoriatic arthritis
In a Phase 2b, 52-week study of 391 adult patients, researchers reported that 71.4% to
79.5% of patients treated with Ilumya had a 20% improvement in symptoms of psoriatic arthritis (ACR20) at week 24, compared to 50.6% of patients on placebo, a significant outcome.
Patients achieved similar results with either the 100 mg or 200 mg dose given every 12 weeks (quarterly) in the 24 week analysis. Some patients using the 100 mg dose had significant improvement as early as 8 weeks.
Ilumya was well-tolerated through 52-weeks of treatment and there was a low rate of serious side effects (3.3%) comparable to placebo. The most common side effects reported included the common cold (nasopharyngitis), upper respiratory tract infections, high blood pressure and headaches. Side effects of any type were reported in 64% of patients.
By week 52, 76 (19.4%) patients discontinued the study, primarily due to lack of efficacy (9.5%) or withdrawn consent (3.3%). The main study limitation was a high rate of placebo response, yet results remained statistically significant.
This is not all the information you need to know about Ilumya (tildrakizumab-asmn) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full product information and discuss any questions you have with your doctor or other health care provider.
References
- Ilumya (tildrakizumab-asmn) Product Information. 7/2020. Sun Pharma. Cranbury, NJ. Accessed August 10, 2021 at https://www.ilumyapro.com/wp-content/uploads/Sun-Pharma_ILUMYA_US_Prescribing-Information-and-Med-Guide_2020.pdf
- Sun Pharma Announces Late-Breaking Phase 2 Data
Showing Potential of Ilumya (tildrakizumab-asmn) to
Improve Joint and Skin Symptoms of Psoriatic Arthritis. Press Release. June 14, 2019. Sun Pharma. Accessed August 10, 2021 at https://www.sunpharmaderm.com/pdf/Press%20Release%20Late-Breaking%20Phase%202%20Data%20Showing%20Potential%20of%20ILUMYA%20for%20PsA.pdf - Mease PJ, et al. Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis: An Interim Analysis. Presented at the Annual European Congress of Rheumatology (EULAR 2019), June 2019.
- Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb studyAnnals of the Rheumatic Diseases Published Online First: 13 May 2021. doi: 10.1136/annrheumdis-2020-219014
- Understanding Unapproved Use of Approved Drugs "Off Label". US Food and Drug Administration. (FDA) Accessed August 10, 2021 at https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
Read next
Related medical questions
- What are the new drugs for plaque psoriasis?
- Why should I take folic acid with methotrexate?
- Is triamcinolone acetonide an antifungal cream?
- How do you use clobetasol propionate on your scalp?
- Clobetasol vs. triamcinolone - how do they compare?
- What is a substitute for fluocinonide cream?
- How long does methotrexate stay in your system?
- Halobetasol vs. clobetasol - How do they compare?
- Does taking vitamin D help with psoriasis?
- What causes Plaque Psoriasis?
- Sotyktu vs Otezla: How do they compare?
- Can clobetasol be used for toenail fungus?
- How does Taltz compare to Cosentyx for psoriatic arthritis?
- How long does it take for Skyrizi to work?
- How long does it take for Otezla to work?
- Is fluocinonide an antifungal cream?
- How long should you use fluocinonide for?
- How long does clobetasol stay in your system?
- How do you inject Humira?
- Does Feverfew interact with any drugs?
- What are 6 key Taltz side effects to watch out for?
- Cosentyx vs Humira: How do they compare?
- What's the dosing schedule for Skyrizi?
- Who is the actress in the Stelara commercial?
- What happens if Cosentyx is not refrigerated?
- Can Enstilar be used on the scalp?
- What does Otezla do to the body?
- What is fluocinonide cream good for?
- How long does it take for Sotyktu to work?
- What is the mechanism of action of infliximab?
Drug information
Related support groups
- Psoriasis (100 questions, 306 members)
- Ilumya (9 questions, 3 members)
- Tildrakizumab (6 questions, 3 members)
- Rheumatoid Arthritis (322 questions, 1,317 members)
- Psoriatic Arthritis (82 questions, 276 members)
- Plaque Psoriasis (84 questions, 69 members)